Cargando…
Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?†
BACKGROUND: To evaluate the efficacy of three additional cycles of chemotherapy in patients with the International Federation of Gynecology and Obstetrics Stage III or IV, who achieved a complete response after six cycles of intravenous adjuvant paclitaxel/carboplatin after surgery. METHODS: The cli...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2435294/ https://www.ncbi.nlm.nih.gov/pubmed/18508785 http://dx.doi.org/10.1093/jjco/hyn034 |
_version_ | 1782156479471550464 |
---|---|
author | Kim, Hee Seung Park, Noh-Hyun Chung, Hyun Hoon Kim, Jae Weon Song, Yong-Sang Kang, Soon-Beom |
author_facet | Kim, Hee Seung Park, Noh-Hyun Chung, Hyun Hoon Kim, Jae Weon Song, Yong-Sang Kang, Soon-Beom |
author_sort | Kim, Hee Seung |
collection | PubMed |
description | BACKGROUND: To evaluate the efficacy of three additional cycles of chemotherapy in patients with the International Federation of Gynecology and Obstetrics Stage III or IV, who achieved a complete response after six cycles of intravenous adjuvant paclitaxel/carboplatin after surgery. METHODS: The clinical data of 94 patients with complete response after six cycles of adjuvant paclitaxel/carboplatin after surgery between January 1997 and March 2007 were reviewed retrospectively. Three additional cycles using the same chemotherapy were administered to 57 patients as consolidation chemotherapy (Group 1). Thirty-seven patients without the additional cycles served as controls (Group 2). Disease-free survival (DFS) and overall survival (OS) were evaluated using the Kaplan–Meier method with the log-rank test. The importance of consolidation chemotherapy as a prognostic factor affecting survival was examined using the Cox's proportional hazard analysis. The incidence of chemotherapy-induced hematological toxicities was compared between the two groups using chi-square test. RESULTS: Median DFS and mean OS were not significantly different between the two groups (15 versus 22 months, P = 0.703; 69 versus 73 months, P = 0.891, respectively). Consolidation chemotherapy was not a prognostic factor of survival although optimal debulking surgery and lower value of serum CA-125 levels after six cycles of the chemotherapy were prognostic factors improving DFS (P < 0.01). Grade 3 or 4 leukopenia was more common in patients treated with consolidation chemotherapy than in those not treated (50.9 versus 21.6%, P = 0.004). CONCLUSION: Consolidation chemotherapy using paclitaxel/carboplatin may be inefficient and relatively toxic to advanced-stage epithelial ovarian cancer patients with complete response to six cycles of the same chemotherapy after surgery. |
format | Text |
id | pubmed-2435294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-24352942009-02-25 Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?† Kim, Hee Seung Park, Noh-Hyun Chung, Hyun Hoon Kim, Jae Weon Song, Yong-Sang Kang, Soon-Beom Jpn J Clin Oncol Original Articles BACKGROUND: To evaluate the efficacy of three additional cycles of chemotherapy in patients with the International Federation of Gynecology and Obstetrics Stage III or IV, who achieved a complete response after six cycles of intravenous adjuvant paclitaxel/carboplatin after surgery. METHODS: The clinical data of 94 patients with complete response after six cycles of adjuvant paclitaxel/carboplatin after surgery between January 1997 and March 2007 were reviewed retrospectively. Three additional cycles using the same chemotherapy were administered to 57 patients as consolidation chemotherapy (Group 1). Thirty-seven patients without the additional cycles served as controls (Group 2). Disease-free survival (DFS) and overall survival (OS) were evaluated using the Kaplan–Meier method with the log-rank test. The importance of consolidation chemotherapy as a prognostic factor affecting survival was examined using the Cox's proportional hazard analysis. The incidence of chemotherapy-induced hematological toxicities was compared between the two groups using chi-square test. RESULTS: Median DFS and mean OS were not significantly different between the two groups (15 versus 22 months, P = 0.703; 69 versus 73 months, P = 0.891, respectively). Consolidation chemotherapy was not a prognostic factor of survival although optimal debulking surgery and lower value of serum CA-125 levels after six cycles of the chemotherapy were prognostic factors improving DFS (P < 0.01). Grade 3 or 4 leukopenia was more common in patients treated with consolidation chemotherapy than in those not treated (50.9 versus 21.6%, P = 0.004). CONCLUSION: Consolidation chemotherapy using paclitaxel/carboplatin may be inefficient and relatively toxic to advanced-stage epithelial ovarian cancer patients with complete response to six cycles of the same chemotherapy after surgery. Oxford University Press 2008-06 2008-05-27 /pmc/articles/PMC2435294/ /pubmed/18508785 http://dx.doi.org/10.1093/jjco/hyn034 Text en © 2008 The Author(s) |
spellingShingle | Original Articles Kim, Hee Seung Park, Noh-Hyun Chung, Hyun Hoon Kim, Jae Weon Song, Yong-Sang Kang, Soon-Beom Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?† |
title | Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?† |
title_full | Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?† |
title_fullStr | Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?† |
title_full_unstemmed | Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?† |
title_short | Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?† |
title_sort | are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin?† |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2435294/ https://www.ncbi.nlm.nih.gov/pubmed/18508785 http://dx.doi.org/10.1093/jjco/hyn034 |
work_keys_str_mv | AT kimheeseung arethreeadditionalcyclesofchemotherapyusefulinpatientswithadvancedstageepithelialovariancancerafteracompleteresponsetosixcyclesofintravenousadjuvantpaclitaxelandcarboplatin AT parknohhyun arethreeadditionalcyclesofchemotherapyusefulinpatientswithadvancedstageepithelialovariancancerafteracompleteresponsetosixcyclesofintravenousadjuvantpaclitaxelandcarboplatin AT chunghyunhoon arethreeadditionalcyclesofchemotherapyusefulinpatientswithadvancedstageepithelialovariancancerafteracompleteresponsetosixcyclesofintravenousadjuvantpaclitaxelandcarboplatin AT kimjaeweon arethreeadditionalcyclesofchemotherapyusefulinpatientswithadvancedstageepithelialovariancancerafteracompleteresponsetosixcyclesofintravenousadjuvantpaclitaxelandcarboplatin AT songyongsang arethreeadditionalcyclesofchemotherapyusefulinpatientswithadvancedstageepithelialovariancancerafteracompleteresponsetosixcyclesofintravenousadjuvantpaclitaxelandcarboplatin AT kangsoonbeom arethreeadditionalcyclesofchemotherapyusefulinpatientswithadvancedstageepithelialovariancancerafteracompleteresponsetosixcyclesofintravenousadjuvantpaclitaxelandcarboplatin |